| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 510.31 |
1-year : | 533.96 |
| Resists | First : | 436.91 |
Second : | 457.16 |
| Pivot price | 434.16 |
|||
| Supports | First : | 404.16 |
Second : | 336.26 |
| MAs | MA(5) : | 431.49 |
MA(20) : | 434.29 |
| MA(100) : | 338.34 |
MA(250) : | 318.35 |
|
| MACD | MACD : | 10.6 |
Signal : | 15.5 |
| %K %D | K(14,3) : | 21.9 |
D(3) : | 36.7 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 457.16 | Low : | 200.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MDGL ] has closed above bottom band by 25.3%. Bollinger Bands are 32.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 428.55 - 430.67 | 430.67 - 432.81 |
| Low: | 414.69 - 416.89 | 416.89 - 419.11 |
| Close: | 420.71 - 424.18 | 424.18 - 427.7 |
Thu, 25 Sep 2025
Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS - The Globe and Mail
Thu, 18 Sep 2025
76 New Hires: Madrigal Pharmaceuticals Awards 31.8K RSUs and Stock Options in MASH Drug Expansion - Stock Titan
Tue, 16 Sep 2025
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Fri, 12 Sep 2025
New Analyst Forecast: $MDGL Given $526.0 Price Target - Quiver Quantitative
Thu, 21 Aug 2025
Insider Sale: President and CEO of $MDGL Sells 6,485 Shares | MDGL Stock News - Quiver Quantitative
Wed, 20 Aug 2025
Madrigal gets EU nod for its MASH treatment (MDGL:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.098e+007 (%) |
| Held by Institutions | 7.7 (%) |
| Shares Short | 3,980 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.084e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -54.7 % |
| Operating Margin | -22.2 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | -36.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 13.81 |
| Sales Per Share | 14.29 |
| EBITDA (p.s.) | -19.1 |
| Qtrly Earnings Growth | -12.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -307 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 29.67 |
| Price to Cash Flow | -13.82 |
| Dividend | 0 |
| Forward Dividend | 4.05e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|